Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive phase 2/3 study of Reparixin in hospitalized patients with COVID-19 pneumonia
2020-001645-40Phase 2Terminated
- Sponsor
- Dompé
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of reparixin in coronavirus pneumonia and viral infection (2 arms), sponsored by Dompé. Primary endpoint: Phase 2 Primary Endpoint. Started Sep 2020; status: terminated.
02
Drugs
reparixin
03
Conditions
coronavirus pneumoniaviral infection
Beyond the preview
Go deeper on 2020-001645-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001645-40.